EUROPEAN PATENT SPECIFICATION

Date of publication of patent specification: 01.10.92
Int. Cl.: A61K 31/55
Application number: 88101785.9
Date of filing: 08.02.88

The file contains technical information submitted after the application was filed and not included in this specification.

Agent having renal function-improving effect and diuretic effect and the use of a benzothiazepin derivative contained therein.

Priority: 10.02.87 JP 29396/87
Date of publication of application: 17.08.88 Bulletin 88/33
Publication of the grant of the patent: 30.09.92 Bulletin 92/40
Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE

References cited:

AM. J. CARDIOL., vol. 59, no. 2, 23 January 1987; P.L.VAGHI et al., pp. 9a-17a*

JAPAN. J. PHARMACOL., vol. 24, 1974; I.YAMAGUSHI et al., pp. 511-522*


CARDIOVASC. DRUGS AND THERAPY, vol. 1, December 1987, Martinus Nijhoff Publishing, Boston, MD (US); T.ISSHIKI et al., pp. 359-366*

Proprietor: TANABE SEYAKU CO., LTD.
2-10, Dosho-machi 3-chome Chuo-ku Osaka(JP)

Inventor: Yamaguchi, Isao
No. 3-16-8, Ogikubo Suginami-ku
Tokyo-to(JP)
Inventor: Akimoto, Yoshiaki
No. 3-19-3-204 Asahi
Kawaguchi-shi Saitama-ken(JP)
Inventor: Nagao, Taku
No. 4-36-21, Kamimeguro Meguro-ku
Tokyo-to(JP)

Representative: Hansen, Bernd, Dr.rer.nat. et al
Hoffmann, Eltle & Partner Patentanwälte Arbellastrasse 4 Postfach 81 04 20 W-8000 München 81(DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).
THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 62, 05 October 1988; T.ISSHIKI et al., pp. 79g-84g*

CARDIOVASC. DRUGS AND THERAPY, vol. 2, no. 4, 1988, Kluwer Academic Publishers (US); T.ISSHIKI et al., pp. 539-547*

ARZNEIM.-FORSCH./DRUG RES., vol. 38 (I), no. 4, 1988; H.NARITA et al., pp. 515-520*
Description

The present invention relates to an agent having a diuretic effect.

It is known that 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzoazepin-4(5H)-one or a pharmaceutically acceptable acid addition salt thereof has excellent hypotensive activity and cerebral or coronary vasodilating activity (Japanese Unexamined Patent Publication No. 225174/1984).


The present invention provides the use of (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzoazepin-4(5H)-one or a pharmaceutically acceptable acid addition salt thereof, for the preparation of a medicament having a diuretic effect.

DESCRIPTION OR THE PREFERRED EMBODIMENTS

The above 8-chloro-benzoazepine compound which is an active ingredient of the present invention has excellent renal function-improving activity and diuretic activity.

For example, in the case where 30 minutes clamping is applied to the renal artery in the rats after contralateral nephrectomy, they suffer from an ischemia-induced acute renal failure. Moreover, when glycerol is intramuscularly administered to rats, they suffer from acute renal failure. In these cases, values of urea nitrogen and creatinine in the blood of the rats is abnormally increased as in the case of human acute renal failure. The 8-chloro-benzoazepine compound which is the active ingredient of the present invention exhibits an excellent effect, whereby these values are very much improved. Also, when a stroke-prone spontaneously hypertensive rat (SHRSP) is fed with a diet containing sodium chloride, renal disorder (azotemia) which is similar to chronic renal failure is caused and kidney lesions (e.g. atrophy of uniforner tubules, collapse or sclerosis of glomerular tufts) may be observed. However, in cases where the 8-chloro-benzoazepine compound which is the active ingredient of the present invention is administered, such lesions in kidney can be prevented. Accordingly, the pharmaceutical preparation comprising the above compound is effective against renal failure in addition to having a diuretic activity.

When the above 8-chloro-benzoazepine compound which is the active ingredient of the present invention is orally administered to SHR (dose: 10 mg/kg), the compound exhibits an excellent effect such that urine volume and amounts of sodium ion and chloride ion excreted in the urine are increased by 70% or more, respectively, without affecting the excretion of potassium. Therefore, the pharmaceutical preparation of the present invention can be used as a diuretic agent without fear of causing hypokalemia.

The agent having a diuretic effect of the present invention can be used in both oral and parenteral administration to a warm-blooded animal including a human being. When used orally, the 8-chloro-benzoazepine compound or a pharmaceutically acceptable acid addition salt thereof can be used as such or in the form of pharmaceutical preparations suitable for oral administration with pharmaceutically acceptable carriers such as excipients, binding agents, disintegrators and lubricants. The pharmaceutically acceptable carriers include, for example, starch, lactose, glucose, gelatin, sorbit, tragacanth, polyvinyl pyrrolidone, sugar, corn starch, polyethylene glycol, talc, potassium phosphate, magnesium stearate and other conventional excipients, binding agents, disintegrators and lubricants. The preparation for administration may be in solid forms such as tablets, capsules, granules, microcapsules and suppositories, or in liquid forms such as solutions, suspensions and emulsions. For parenteral administration, the agent of the present invention may be suitably used in the form of injections. As solvent for injection, distilled water, vegetable oil and propylene glycol can be used. Further, the injectable composition may contain solubilizers, buffers and stabilizers.

The 8-chloro-benzoazepine compound, which is the active ingredient of the present invention, can be used in the form of a free base or a pharmaceutically acceptable acid addition salt thereof. The pharmaceutically acceptable acid addition salt can be, for example, an inorganic acid salt such as hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate or phosphate, or an organic acid salt such as oxalate, maleate, fumarate, tartarate or methanesulfonate.

The dose of the agent used according to the present invention may vary depending on the disease condition, the age, body weight and severity of symptoms of the patient and on the administration route, but the proper dose of the 8-chloro-benzoazepine compound or a pharmaceutically acceptable acid addition salt thereof may be in the range of 0.05 to 100 mg/day/kg, preferably in the range of 0.1 to 30 mg/day/kg.
As mentioned above, the agent of the present invention has the effect of improving abnormalities in the concentrations of urea nitrogen and creatinine in blood under the state of renal failure, as well preventing kidney lesions in cases of chronic renal failure, and therefore is also effective against acute and chronic renal failure resulting from various renal diseases such as glomerulonephritis, nephrotic syndrome, nephrosclerosis, tubular disorder and ischemic renal failure.

Since the agent of the present invention has the effect of increasing urine volume and the amounts of sodium ion and chloride ion in the urine without affecting the excretion of potassium, it can be used for the treatment of the symptoms of edema and renal failure, and as a diuretic agent which has no risk of causing hypokalemia.

Experimental example 1

(Effect on ischemic acute renal failure)

(+)-Cis-2-{4-methoxyphenyl}-3-acetoxo-5-[2-(dimethylamino) ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate was used as the test compound.

Ischemic acute renal failure (ARF) was induced in male Sprague-Dailey rats (one group consisting of 11 rats) weighing 270 to 360 g. They were fasted overnight and anesthetized with pentobarbital Na (50 mg/kg i.p.). After right nephrectomy, the left renal artery was clamped for 30 minutes. An intravenous infusion of saline or the test compound solution was started in all animals 15 minutes before the initiation of clamping and was continued during the 30-minutes clamping period. The abdominal wall was closed and the rats were placed in individual cages. Urine was collected for 24 hours under free access to food and water. 24 Hours later, blood was drawn for analysis.

Three groups of rats studied were as follows:
1) Sham operated rats (sham)
2) Untreated control animals with ischemic ARF. (ARF control)
3) Ischemic ARF, treated by the intravenous infusion of the test compound at a rate of 20 μg/kg/min.

Plasma urea and creatinine, and urine creatinine, sodium, osmolarity and NAG (N-acetyl-β-D-Glucosaminidase) were determined by standard methods. Creatinine clearance, fractional excretion of sodium and NAG index were calculated with standard formulas.

(Results)

The results are shown in Table 1.
Table 1

<table>
<thead>
<tr>
<th>Dose (µg/kg/min)</th>
<th>PUN (mg/dl)</th>
<th>Pcr (mg/dl)</th>
<th>FENA (%)</th>
<th>Ccr (ml/24h)</th>
<th>Uosm (mOsm/kg H₂O)</th>
<th>NAGindex (Unit of creatinine)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>23.2 ± 1.7</td>
<td>0.7 ± 0.04</td>
<td>0.5 ± 0.10</td>
<td>1589 ± 105</td>
<td>1286 ± 123</td>
<td>33.8 ± 5.6</td>
</tr>
<tr>
<td>ARF Control</td>
<td>101.0###</td>
<td>3.3##</td>
<td>9.67###</td>
<td>236###</td>
<td>598###</td>
<td>83.5###</td>
</tr>
<tr>
<td>20</td>
<td>63.7###</td>
<td>1.7*</td>
<td>2.90</td>
<td>816###</td>
<td>818###</td>
<td>66.6###</td>
</tr>
</tbody>
</table>

*P < 0.05, ###P < 0.01 vs Sham Group
**P < 0.05, ***P < 0.01 vs ARF Control Group

PUN; Plasma Urea Nitrogen Concentration
Pcr; Plasma Creatinine Concentration
FENA; Fractional Excretion of Sodium
Ccr; Creatinine Clearance
Uosm; Urine Osmolarity
NAGindex; N-Acetyl-β-D-Glucosaminidase index

As can be seen from Table 1, twenty-four hours after the ischemic insult, the untreated control rats caused marked increases in plasma urea (PUN) and creatinine (Pcr) levels and a significant decrease in creatinine clearance (Ccr) value. These rats also had higher fractional excretion of sodium (FENA) and NAG index, and lower urinary osmolarity (Uosm). Thus, the untreated control rats showed an acute renal failure (ARF).

ARF rats treated with the test compound (20 µg/kg/min) exhibited significantly lower PUN, Pcr, FENA and NAG index, and higher Ccr than those in the untreated control rats.

This means that the test compound is effective in reducing the severity of ischemic acute renal failure.

Experimental example 2

(Effect on glycerol-induced acute renal failure in rats)

To SD strain male rats (age: 7 weeks; one group consisting of 4 to 5 rats) dehydrated for 24 hours there was administered intramuscularly at femoral region a 50% glycerol-physiological saline at a dose of 10 ml/kg.

In order to examine the effect of the present pharmaceutical preparation on the acute renal failure induced under such experimental conditions, an aqueous solution of (+)-cis-2-(4-methoxyphenyl)-3-acetoxymethylaminomethyl-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate at doses of 10 mg/kg and 30 mg/kg, respectively, was administered orally to the test compound administration groups at a prescribed time of the day for the three days before the administration of glycerol. After administration of the glycerol, the test compound was orally administered in the similar manner.

On the other hand, water was orally administered to the control group instead of the test compound solution.

After three days of the administration of the glycerol, celiotomy was conducted for the rats of both groups under ether anesthesia, and blood was collected from the abdominal aorta. Then, serum separated from said blood was subjected to a biochemical analysis.
Results are shown in Table 2 below.

Table 2

<table>
<thead>
<tr>
<th>Test compound administration group (dose: mg/kg/day)</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>30</td>
</tr>
</tbody>
</table>

Serum urea nitrogen (mg/dl) 81.3±39.4 66.4±13.1 119.1±89.3

Serum creatinine (mg/dl) 1.68±0.68 1.28±0.14 3.37±1.41

From the above Table, it can be recognized that the concentrations of serum urea nitrogen and creatinine are remarkably increased in the control group with acute renal failure. However, in the test compound administration group, the concentrations are lowered dose-dependently in both cases, and therefore it is apparent that the onset of acute renal failure is inhibited.

Experimental example 3

(Effect on chronic renal failure in rats)

Stroke-prone spontaneously hypertensive rats (SHRSP, age: 13 weeks, one group consisting of 8 rats) were fed with a powder diet containing 8% sodium chloride for three weeks. In order to examine the effect of the pharmaceutical preparation of the present invention on chronic renal failure induced under such conditions, the test compound administration group was fed with a powder diet containing 8% sodium chloride and 1000 ppm of (+)-cis-2-[(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate for three weeks. On the other hand, the control group was fed with a powder diet containing 8% sodium chloride for 3 weeks.

After the feeding, celiotomy was conducted for each rat under ether anesthesia, and blood was collected from the abdominal aorta and then the rats were killed. The collected blood was subjected to a biochemical analysis, and the kidney was subjected to a histopathological examination.

Results are shown in Table 3 below.
### Table 3

<table>
<thead>
<tr>
<th>Test compound administration group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrophy of uriniferous tubule</td>
<td></td>
</tr>
<tr>
<td>0/8</td>
<td>2/8</td>
</tr>
<tr>
<td>△</td>
<td>△</td>
</tr>
<tr>
<td>0/8</td>
<td>5/8</td>
</tr>
<tr>
<td>△</td>
<td>△</td>
</tr>
<tr>
<td>Collapse or sclerosis of glomerular tuft</td>
<td></td>
</tr>
<tr>
<td>0/8</td>
<td>3/8</td>
</tr>
<tr>
<td>△</td>
<td>△</td>
</tr>
<tr>
<td>0/8</td>
<td>7/8</td>
</tr>
<tr>
<td>△</td>
<td>△</td>
</tr>
<tr>
<td>Proteinaceous casts</td>
<td></td>
</tr>
<tr>
<td>0/8</td>
<td>0/8</td>
</tr>
<tr>
<td>△</td>
<td>△</td>
</tr>
<tr>
<td>0/8</td>
<td></td>
</tr>
<tr>
<td>△</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>0.58±0.02*</td>
<td>0.68±0.02</td>
</tr>
</tbody>
</table>

In the above Table, *, △ and ▲ have the following meanings:

*: p<0.01

**Atrophy of uriniferous tubule**

△ means the case where uriniferous tubule accompanied with epithelial cell with reduced staining properties, luminal constriction and winding basement membrane can be observed at the area of not less than 30% and less than 60% on the cut surface of kidney.

▲ means the case where the above changes are observed at the area of 60% or more on the cut surface of kidney.

**Collapse or sclerosis of glomerular tuft**

△ means that collapse or sclerosis of glomerular tufts are observed in 30% or more and less than 60% of the total glomeruli on the cut surface.

▲ means the above changes are observed in 60% or more of the total glomeruli on the cut surface.

**Proteinaceous cast**

△ means that the proteinaceous casts are scattered at the cortical part.

▲ means that the proteinaceous casts are observed extensively at the cortical part.

From Table 3, in the control group, histopathological changes such as atrophy of uriniferous tubule, collapse or sclerosis of glomerular tuft and proteinaceous casts which mean the presence of proteinuria, are remarkable. On the contrary, in the test compound administration group, it is apparent that such renal lesions are not recognized.

Also, in the control group, since the serum creatinine is increased, it can be seen that rats of the control group are clinically suffering from renal failure. However, in the test compound administration group, such phenomena are not observed at all.
Experimental example 4

(Effect on electrolyte balance and urine volume)

Groups of 10 male SHR weighing 335 to 415 g were fasted overnight and then 2.5 ml/100 g of physiological saline were administered orally. One hour later, the rats were given (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate dissolved in physiological saline at prescribed concentrations. Rats of the control group were given orally 2.5 ml/100 g of physiological saline instead of the test compound solution. Immediately afterwards, the animals were individually housed in a metabolic cage for 5 h. The urine excreted during this period was collected and its volume was measured. The concentrations of electrolytes (sodium, potassium and chloride ions) in the urine were determined and the amounts excreted were calculated.

(Results)

The results are shown in Table 4.
As clearly shown in Table 4, the 8-chloro-benzothiazpine compound, which is an active ingredient of the present invention at the dose of 10 mg/kg increased the urine volume by 73% and the excretion of sodium and chloride ions by 96 and 77%, respectively, in comparison with those of the control group. However, the compound did not affect the excretion of potassium ion and therefore significantly increased the sodium/potassium ratio in the urine.
Example 1

(Tablet)

(+)-Cis-8-chloro-benzothiazepine compound

(maleate)  45.0 g
Corn starch  20.1 g
Lactose  82.4 g
Polyvinyl pyrrolidone  3.0 g
Crystalline cellulose  38.0 g
Magnesium stearate  1.5 g

Total  190.0 g

The (+)-cis-8-chlorobenzothiazepine compound (maleate), lactose and corn starch were mixed with an alcohol solution of polyvinyl pyrrolidone and granulated by kneading according to the wet granulation method, followed by drying to be formed into granules.

Subsequently, magnesium stearate and crystalline cellulose were added to the granules and the mixture was compressed by a tabletting machine to give tablets of 8 mm in diameter and 190 mg in weight.

Example 2

(Injection)

Ten grams of (+)-cis-8-chlorobenzothiazepine compound (maleate) were dissolved in 2 liter of distilled water for injection. The solution was filtered through a membrane filter with a pore size of 0.22 μm, and was poured into ampoules under aseptic conditions to give 2 ml per ampoule and the latter were sealed to give ampoules for injection.

Example 3
(Powders)

(+)-Cis-8-chlorobenzothiazepine compound

(maleate) 10 g

Lactose 90 g

Total 100 g

The above-mentioned ingredients were homogeneously mixed in a double conical mixer to give 10-fold trituration.

Claims

1. Use of (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one or a pharmaceutically acceptable acid addition salt thereof, for the preparation of a medicament having a diuretic effect.

2. The use according to claim 1, wherein said pharmaceutically acceptable acid addition salt is selected from hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, phosphate, oxalate, maleate, fumarate, tartarate and methanesulfonate.

3. The use according to Claim 2, wherein said pharmaceutically acceptable acid addition salt is maleate.

Patentansprüche

1. Verwendung von (+)-cis-2-(4-Methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-on oder eines pharmazeutisch verträglichen Säureadditionssalzes hiervon zur Herstellung eines Arzneimittels mit diuretischer Wirkung.

2. Verwendung nach Anspruch 1, wobei das pharmazeutisch verträgliche Säureadditionssalz aus Hydrochlorid, Hydrobromid, Hydroiodid, Perchlorat, Sulfat, Phosphat, Oxalat, Maleat, Fumarat, Tartrat und Methansulfonat ausgewählt ist.

3. Verwendung nach Anspruch 2, wobei das pharmazeutisch verträgliche Säureadditionssalz Maleat ist.

Revendications

1. Utilisation de la (+)-cis-2-(4-méthoxyphényl)-3-acétoxy-5-[2-(diméthylamino)éthyl]-8-chloro-2,3-dihydro-1,5-benzothiazépin-4(5H)-one ou d’un de ses sels d’addition aux acides pharmaceutiquement acceptables pour la préparation d’un médicament ayant un effet diurétique.

2. Utilisation selon la revendication 1, dans laquelle ce sel d’addition aux acides pharmaceutiquement acceptable est choisi parmi le chlorhydrate, le bromhydrate, l’iodhydrate, le perchlorate, le sulfate, le phosphate, l’oxalate, le maléate, le fumarate, le tartrate et le méthanesulfonate.

3. Utilisation selon la revendication 2, dans laquelle ce sel d’addition aux acides pharmaceutiquement acceptable est le maléate.